There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for NGM Biopharmaceuticals Inc. (NGM) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.04, or -0.80%, to $4.98. The NGM Biopharmaceuticals Inc. has recorded 18,985 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $5.02 and fluctuated between $5.02 as its day high and $4.79 as its day low. The current market capitalization of NGM Biopharmaceuticals Inc. is $397.99M. A total of 0.37 million shares were traded on the day, compared to an average of 969.55K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, NGM has seen 28 BUY and 0 SELL insider trades, representing the acquisition of 1,377,900 and the disposition of 0 shares. Over the last 12 months, there were 160 BUYs and 0 SELLs from insiders. Insiders purchased 9,599,757 shares during that period but sold 0.
In the most recent transaction, COLUMN GROUP L P bought 300 shares of NGM for 4.98 per share on Dec 12. After the transaction, the Director now owns 380,472 company shares. In a previous transaction on Dec 12, COLUMN GROUP L P bought 300 shares at 4.98 per share. NGM shares that Director owns now total 380,472.
Among the insiders who bought shares, COLUMN GROUP L P acquired of 300 shares on Dec 12 at a per-share price of $4.98. This resulted in the Director holding 380,472 shares of NGM after the transaction. In another insider transaction, GOEDDEL DAVID V bought 300 shares at $4.98 per share on Dec 12. Company shares held by the Director now total 380,472.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for NGM in the last 3 months, the mean price target is $5.83 with high estimates of $9.00 and low estimates of $4.00. In terms of 52-week highs and lows, NGM has a high of $19.14 and a low of $2.92.
As of this writing, NGM has an earnings estimate of -$0.59 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.51 per share and a lower estimate of -$0.68. The company reported an EPS of -$0.42 in the last quarter, which was 8.70% higher than expectations of -$0.46.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NGM is Overweight with a score of 3.83. A total of 2 analysts rated the stock as Buy while 1 rated it as Overweight while 3 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.